Cipher Pharmaceuticals (TSE:CPH) Stock Price Crosses Above Fifty Day Moving Average - Here's Why

Cipher Pharmaceuticals Inc. (TSE:CPH - Get Free Report) NASDAQ: CPHR crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$14.60 and traded as high as C$14.82. Cipher Pharmaceuticals shares last traded at C$14.74, with a volume of 6,877 shares traded.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Stifel Nicolaus lowered their price objective on shares of Cipher Pharmaceuticals from C$19.00 to C$17.00 in a research report on Monday, November 11th. Leede Financial cut shares of Cipher Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 13th.

Cipher Pharmaceuticals Stock Down 3.1 %

The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.67 and a current ratio of 11.18. The stock has a market cap of C$365.43 million, a price-to-earnings ratio of 11.42 and a beta of 1.20. The firm's 50-day simple moving average is C$14.59 and its two-hundred day simple moving average is C$14.03.

Cipher Pharmaceuticals (TSE:CPH - Get Free Report) NASDAQ: CPHR last issued its earnings results on Thursday, November 7th. The company reported C$0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.03 by C($0.02). The business had revenue of C$14.15 million during the quarter, compared to the consensus estimate of C$13.37 million. Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%. On average, sell-side analysts expect that Cipher Pharmaceuticals Inc. will post 1.2907348 EPS for the current fiscal year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.